© August 2025 | IJIRT | Volume 12 Issue 3 | ISSN: 2349-6002

One Health Perspective on UTI-Causing E. coli: Linking Human, Animal, and Environmental Factors in Resistance Spread

Bisuddha Maiti[1], Mohammad Moushen Reshi[2], Bhawna Suryawanshi[3]
[1]*Medical Lab Instructor, Department of Paramedical Science,*
[2]*BSC Medical Lab Science, Department of Paramedical Science,*
[3]*Assistant Professor, Department of Paramedical Science,*
Swami Vivekanand Group of Institutes, Banur

Abstract- **In a world invisibly stitched together by microbes, Escherichia coli, a familiar gut dweller, has become a stealthy global threat, fueling a silent pandemic of urinary tract infections (UTIs) resistant to once-reliable antibiotics. This paper unravels the complex web of antimicrobial resistance (AMR) through a One Health lens, where the worlds of humans, animals, and the environment intersect. From overprescribed pills in urban hospitals to antibiotic-laced feed on rural farms and genes floating freely in wastewater streams, we trace the pathways through which E. coli evolves, adapts, and spreads its arsenal of resistance. With genomic evidence linking hospital strains to poultry, rivers, and soil, the illusion of microbial boundaries dissolves, revealing a unified battlefield. We explore how social behavior, economic incentives, climate shifts, and policy gaps fuel this microbial insurgency, and how cutting-edge innovations, such as phage therapy and rapid diagnostics, offer hope. Drawing from global data, regional case studies, and cross-species genetic signatures, the study calls for more than surveillance; it demands solidarity. In this microbial era, where a single resistant strain can traverse continents undetected, the future of infection control lies in a united strategy. One planet. One pathogen. One Health.**

Index Terms- **microbes, reliable, overprescribed, illusion, phage therapy, genetic**

I. INTRODUCTION

Antimicrobial resistance (AMR) has emerged as a critical global health threat, jeopardizing the efficacy of modern medicine and the ability to treat common infectious diseases. The World Health Organization (WHO) recognizes AMR as one of the top 10 global public health threats facing humanity, attributing nearly 5 million deaths annually to drug-resistant infections, with approximately 1.27 million deaths directly attributable to AMR as of 2019 (Murray et al., 2022). A primary driver of AMR is the inappropriate and excessive use of antimicrobials in human health, veterinary medicine, agriculture, and environmental systems, creating a complex web of transmission across sectors. In this context, the One Health approach has emerged as a transformative and integrative framework that recognizes the interdependence of human, animal, and environmental health. Rather than viewing health threats in isolation, One Health promotes interdisciplinary collaboration among physicians, veterinarians, ecologists, microbiologists, and policymakers to holistically address the drivers of AMR. The One Health Joint Plan of Action (2022–2026) launched by WHO, FAO, WOAH, and UNEP emphasizes AMR surveillance, multisectoral risk mitigation, and sustainable antimicrobial stewardship across domains.

Conceptual Framework of One Health in Combating AMR

The conceptual underpinning of One Health in combating AMR lies in understanding the tripartite transmission cycle between humans, animals, and the environment, with antimicrobial-resistant pathogens and genes circulating through this interconnected ecosystem. A diagrammatic framework (see Figure 1, suggested for inclusion) visualizes this triangle:

- Humans: Inappropriate antibiotic use in clinical settings, self-medication, and lack of adherence to prescription regimens drive resistance.
- Animals: Extensive and often unregulated use of antibiotics in livestock and aquaculture for growth promotion and disease prevention contributes significantly to the development of resistant bacteria such as *E. coli*.

- Environment: Effluents from pharmaceutical manufacturing units, hospital wastewater, and agricultural runoff contaminate natural water bodies, acting as reservoirs and transmission pathways for AMR.



Mechanisms such as horizontal gene transfer, mobile genetic elements, and biofilm formation allow resistant genes to spread rapidly across species and ecosystems. Therefore, a One Health conceptual model not only maps microbial transmission routes but also guides intervention points for policy and practice, such as improved antimicrobial stewardship, water-sanitation-hygiene (WASH) infrastructure, and integrated surveillance systems. Urinary tract infections (UTIs) represent one of the most prevalent bacterial infections globally, with over 150 million cases annually, predominantly caused by *Escherichia coli* (Flores-Mireles et al., 2015). These infections impose a significant healthcare burden due to increased hospital stays, medical costs, and risk of complications like pyelonephritis and sepsis. A worrying trend in recent decades is the rise of multidrug-resistant (MDR) *E. coli* strains, particularly those producing extended-spectrum beta-lactamases (ESBLs) and carbapenems. In regions such as South Asia, sub-Saharan Africa, and Latin America, resistance rates to first-line antibiotics like trimethoprim-sulfamethoxazole, fluoroquinolones, and third-generation cephalosporins exceed 50% (WHO GLASS Report, 2023).

1. EPIDEMIOLOGY OF UTI- CAUSING E. COLI

The global epidemiology of urinary tract infections (UTIs) caused by *Escherichia coli* reflects a complex interplay of biological, environmental, and anthropogenic factors. Within the One Health paradigm, understanding the transmission dynamics and burden of UTI-causing *E. coli* requires a multi-sectoral approach that encompasses human medicine, veterinary science, and environmental health.

2.1 Prevalence and Incidence in Human Populations

Global Estimates and Trends

According to the World Health Organization (2024), over 150 million UTIs are reported globally each year, with *E. coli* accounting for the majority (80–85%) of cases in healthy individuals and 65–75% in nosocomial infections. The burden is disproportionately higher in females due to anatomical predisposition, with 50–60% of women experiencing at least one UTI in their lifetime.

Table 1: Global Incidence of UTI by Region (2024 Estimates)

Region	Annual UTI Cases (Millions)	*E. coli* Contribution (%)
North America	10.4	82%
Europe	12.2	83%
Sub-Saharan Africa	14.5	77%
South-East Asia	21.0	85%
Latin America	9.3	80%

Source: Global Burden of Disease Study (2024)

The table highlights the regional burden of urinary tract infections (UTIs) and the predominant role of *Escherichia coli* as the causative agent. South-East Asia reports the highest annual UTI cases at 21 million, with *E. coli* responsible for 85% of infections, the highest contribution among all regions. Sub-Saharan Africa follows with 14.5 million cases and a slightly lower *E. coli* contribution of 77%, possibly indicating a more diverse range of pathogens or diagnostic limitations. Europe and North America record 12.2 and 10.4 million cases, respectively, with *E. coli* accounting for 83% and 82% of infections, reflecting consistent microbial patterns despite advanced healthcare systems. Latin America, with 9.3 million cases and 80% *E. coli* involvement, shows a similar trend. Overall, the data underscores the global dominance of *E. coli* in UTIs, while revealing regional variations in disease burden that are influenced by population size, healthcare access, and ecological factors, highlighting the need for a comprehensive One Health strategy to tackle antimicrobial resistance.

- **Zoonotic transmission: evidence from veterinary and public health studies**

The zoonotic transmission of *Escherichia coli*, particularly strains causing urinary tract infections (UTIs), represents a critical but often underrecognized bridge in the One Health continuum. While UTIs are commonly viewed as non-zoonotic and confined to human populations, growing interdisciplinary evidence has disrupted this siloed understanding, revealing a dynamic transmission interface between humans and animals that is mediated by both direct contact and shared environmental reservoirs. Recent **veterinary epidemiological studies** have illuminated how domestic animals, livestock, and even wildlife can serve as reservoirs or amplifiers of multidrug-resistant (MDR) *E. coli* strains. These strains, frequently isolated from the gastrointestinal tracts of animals, exhibit genotypic and phenotypic similarities to human UTI-causing *E. coli*, particularly those belonging to sequence type ST131, a globally disseminated and highly virulent clone. Companion animals such as dogs and cats, often in close contact with humans, have been found to carry UTI-associated extraintestinal pathogenic *E. coli* (ExPEC), posing a bidirectional transmission risk. This is especially concerning in households with immunocompromised individuals or recurrent UTI patients, where shared microbiomes facilitate bacterial exchange. In the **agricultural domain**, industrial animal farming intensifies this problem. Antibiotics are routinely used for disease prevention and growth promotion in livestock, creating a selective pressure that fosters resistant *E. coli* strains. These bacteria can enter the human food chain via undercooked meat, contaminated dairy products, or through occupational exposure among farm workers and slaughterhouse employees. A seminal study from the Netherlands demonstrated identical extended-spectrum beta-lactamase (ESBL)-producing *E. coli* strains in poultry and human UTI cases, establishing a probable foodborne zoonotic link.

Public health surveillance has begun to bridge the gap between veterinary and human data. Whole-genome sequencing (WGS) analyses and plasmid profiling from clinical and non-clinical sources across countries have provided high-resolution evidence of interspecies genetic overlap. In Brazil, for instance, *E. coli* strains isolated from pigs were found to harbor plasmids identical to those in human ExPEC strains, suggesting horizontal gene transfer across species and environments. Environmental interfaces further complicate this web. Manure runoff from livestock farms contaminates soil and water bodies, facilitating the dissemination of resistant *E. coli* into ecosystems frequented by both humans and wildlife. Public health studies from India and Southeast Asia have reported resistant *E. coli* in rural water sources, which serve as a direct link between agricultural activities and human exposure, particularly in low-resource settings with inadequate sanitation. Zoonotic transmission of UTI-causing *E. coli* is not a fringe phenomenon but a central pillar of antimicrobial resistance (AMR) ecology. It reinforces the need for **integrated surveillance systems**, **veterinary stewardship programs**, and **public health policies** that transcend traditional boundaries. The One Health lens brings much-needed clarity to the complex and entangled pathways of *E. coli* transmission, revealing that safeguarding human health cannot be achieved without addressing microbial dynamics in animals and the environment.

- Comparative burden in developed vs. developing countries

Urinary tract infections (UTIs) caused by *Escherichia coli* are a significant public health concern across the globe. However, the burden, drivers, and implications of these infections vary markedly between developed and developing countries. These disparities are shaped by a complex interplay of healthcare infrastructure, antibiotic usage patterns, sanitation practices, veterinary practices, and regulatory mechanisms, all critical factors within the One Health framework.

1. Burden of UTI-Causing* E. coli*: A Global Comparison

Region	**Estimated Annual UTI Cases (Millions)**	**% Attributed to *E. coli***	**MDR *E. coli* Prevalence**	**Key Challenges**
North America	10.4	82%	~35%	Over-prescription in outpatient settings
Europe	12.2	83%	~30%	Aging population, cross-border healthcare
Sub-Saharan Africa	14.5	77%	~60%	Poor sanitation, high self-medication rates
South-East Asia	21.0	85%	~65%	OTC antibiotic access, inadequate surveillance
Latin America	9.3	80%	~50%	Insufficient veterinary regulation, urban-rural healthcare gaps

- *Source: WHO, CDC, Global Antimicrobial Resistance Surveillance System (GLASS), 2024–2025*

The global burden of urinary tract infections (UTIs) caused by *E. coli* reveals significant regional disparities, both in prevalence and antimicrobial resistance. South-East Asia reports the highest annual UTI cases at 21 million, with 85% attributed to *E. coli* and a concerning 65% prevalence of multidrug-resistant (MDR) strains, largely due to over-the-counter antibiotic availability and weak surveillance systems. Sub-Saharan Africa follows with 14.5 million cases and a 77% *E. coli* attribution, yet exhibits the highest MDR rate (~60%) amid poor sanitation and rampant self-medication. In Latin America, 80% of 9.3 million cases are linked to *E. coli*, and MDR prevalence reaches ~50%, worsened by weak veterinary regulations and rural health disparities. Europe and North America, despite robust healthcare systems, face 12.2 and 10.4 million cases, respectively, with MDR prevalence of ~30–35%. Challenges include antibiotic overuse in outpatient settings, aging populations, and cross-border health dynamics.

In **developed countries**, despite better regulation, antibiotic overuse in outpatient settings, particularly fluoroquinolones and cephalosporins, has led to the rise of drug-resistant *E. coli* strains. However, stringent prescription policies, antimicrobial stewardship programs, and robust diagnostics have helped mitigate widespread resistance. Developed countries have implemented stricter veterinary guidelines and phased out growth-promoting antibiotics. In **developing nations**, over-the-counter (OTC) antibiotic availability, absence of prescription controls, and use of antibiotics in animal husbandry without veterinary oversight are rampant. These practices lead to environmental contamination and cross-transmission between animals and humans, fueling AMR. Poor sanitation and lack of access to clean water in developing regions enable fecal-oral transmission of *E. coli*, including resistant strains. Inadequate wastewater treatment systems often recycle resistant bacteria into community water supplies, increasing human exposure. In many **developing economies**, antibiotics are routinely administered to livestock as growth promoters. Without surveillance, resistant *E. coli* strains from animals enter the human ecosystem via contaminated meat, dairy, and produce

2. ANTIMICROBIAL RESISTANCE MECHANISMS IN E. coli

The global threat of antimicrobial resistance (AMR) is intricately tied to the evolutionary adaptability of microorganisms like *Escherichia coli*, a primary uropathogen responsible for millions of urinary tract infections (UTIs) annually. From the One Health lens, which unifies the health of humans, animals, and the environment, understanding the molecular and ecological mechanisms underpinning resistance in *E. coli* is central to devising integrated interventions. This section delves into the genetic foundation of resistance, the dynamics of horizontal gene transfer (HGT), and the environmental resilience of mobile genetic elements (MGEs), forming a tripartite framework that reflects the intersectoral complexity of AMR propagation.

I. Genetic Basis of Resistance in *E. coli*

The capacity of *E. coli* to acquire and express diverse resistance genes underpins its status as both a clinical and environmental sentinel of AMR. Central to this resistance are several key genes and mechanisms:

- **Extended-Spectrum β-Lactamases (ESBLs)**: Among the most pervasive resistance factors, ESBLs such as *blaCTX-M*, *blaTEM*, and *blaSHV* confer resistance to third-generation cephalosporins. The *CTX-M* family, particularly *blaCTX-M-15*, has emerged as a dominant gene in both community and hospital-acquired UTIs. Its widespread occurrence in humans, poultry, and aquatic environments exemplifies its One Health relevance.
- **Carbapenemases**: Genes like *New Delhi Metallo-β-lactamase-1* (*NDM-1*) have garnered global attention due to their potent carbapenem resistance and pandemic potential. First identified in a patient in India, *NDM-1* now circulates widely in both hospital sewage and livestock environments, highlighting cross-sectoral transmission routes.
- **Colistin Resistance (mcr genes)**: The emergence of *mcr-1* and related genes marks a troubling shift, as colistin represents a last-resort antibiotic for multidrug-resistant infections. Originally traced to pig farms in China, *mcr-1* has since been detected in humans, retail meats, and rivers, indicating horizontal spread across One Health domains.
- **Aminoglycoside-Modifying Enzymes and Efflux Pumps**: Resistance to aminoglycosides and fluoroquinolones in *E. coli* often arises via chromosomal mutations or plasmid-mediated genes (e.g., *aac*, *aph*, *qnr* families). These genes not only hinder treatment efficacy but also coexist with β-lactamase genes on the same MGEs, compounding therapeutic challenges.

Table 1: Key AMR Genes in *E. coli*, Their Antibiotic Classes, and Transmission Modes

Gene	**Antibiotic Class**	**Mechanism of Resistance**	**Common Transmission Mode**	**One Health Relevance**
blaCTX-M	Extended-spectrum β-lactams	β-lactamase enzyme hydrolyzes cephalosporins	Plasmid-mediated conjugation	Found in humans, animals, and water bodies
NDM-1	Carbapenems	Metallo-β-lactamase enzyme	Plasmid, transposon	Hospital sewage, livestock, and rivers
mcr-1	Polymyxins (Colistin)	Phosphoethanolamine transferase enzyme	Plasmid	Livestock, meat, human gut, WWTPs
qnrS	Fluoroquinolones	DNA gyrase protection	Plasmid, integron	Co-carried with ESBLs in poultry and humans
aac(6')-Ib	Aminoglycosides	Acetyltransferase enzyme inactivating drugs	Plasmid, integron	Found in hospital isolates and animal microbiota

The table summarizes key antimicrobial resistance (AMR) genes, their antibiotic targets, resistance mechanisms, transmission modes, and relevance to the One Health framework. Genes like **blaCTX-M** and **NDM-1** confer resistance to β-lactams and carbapenems through enzyme production, spreading via plasmids across humans, animals, and environments. **mcr-1** provides colistin resistance, common in livestock and wastewater. **qnrS** protects DNA gyrase against fluoroquinolones and often co-exists with other resistance genes in poultry and humans. **aac(6')-Ib** inactivates aminoglycosides and is found in both clinical and animal sources. These genes highlight the interconnected nature of AMR transmission across sectors, necessitating integrated surveillance and control strategies.

II. Horizontal Gene Transfer Across Human-Animal-Environment Interfaces

Resistance in *E. coli* is not solely a product of spontaneous mutation—it thrives through *horizontal gene transfer* (HGT), allowing the rapid dissemination of resistance traits across unrelated strains and species. This process, fueled by conjugation, transformation, and transduction, is particularly concerning in a One Health context, where boundaries between ecological niches are increasingly porous.

- **Conjugation**: This mechanism enables plasmids carrying resistance genes (like *blaCTX-M* or *mcr*) to transfer between bacterial cells in the gut microbiomes of humans, livestock, and wildlife. For instance, similar resistance plasmids have been isolated from *E. coli* in both hospitalized patients and poultry farms, suggesting bidirectional transmission.
- **Environmental Reservoirs**: Wastewater treatment plants (WWTPs), agricultural runoff, and open drainage systems serve as melting pots for HGT. In India and many developing countries, untreated sewage from hospitals and animal farms creates hotspots where resistance genes amplify and cross species barriers.
- **Global Mobility and Food Chains**: International travel, food trade, and animal product consumption facilitate the global movement of resistant *E. coli* strains. This underscores the need for synchronized surveillance systems integrating veterinary, human, and environmental health data.

III. Mobile Genetic Elements and Environmental Persistence

The engine of resistance spread lies in *mobile genetic elements*—transposons, integrons, plasmids, and insertion sequences—that shuttle resistance genes within and between genomes. These elements ensure that resistance traits are not only transmitted but also maintained and expressed under varying environmental conditions.

- **Plasmids**: Large plasmids often harbor multiple resistance genes along with virulence factors, making *E. coli* both harder to treat and more pathogenic. Plasmid replicons like IncF, IncI1, and IncX4 are frequently implicated in resistance gene mobility.
- **Integrons and Transposons**: Integrons, especially class 1 integrons, act as gene-capturing systems, collecting resistance cassettes and promoting their expression. Transposons such as Tn3 and Tn4401 contribute to the mobilization of carbapenemases like *blaKPC* and *blaNDM*.
- **Environmental Persistence**: Resistance-carrying MGEs are remarkably stable in aquatic and soil environments, even in the absence of antibiotic selection pressure. Studies have shown the presence of *mcr*, *blaCTX-M*, and *NDM-1* genes in river sediments, agricultural fields fertilized with manure, and biofilms in industrial effluents. This persistence not only sustains AMR but also poses a long-term threat to ecological and public health.

Table 2: Evidence of Identical Resistance Genes/Plasmids Across One Health Domains

Resistance Gene/Plasmid	**Source 1**	**Source 2**	**Source 3**	**Key Study/Region**
blaCTX-M-15	Human urine samples	Poultry gut flora	River sediment	India, Nigeria, Europe
NDM-1	Hospital sewage	Cattle farms	Wastewater effluent	India, Pakistan, UK
mcr-1	Pig intestine (China)	Chicken meat	Urban wastewater	China, Brazil, Germany
IncFII plasmid (carrying *blaCTX-M*)	Blood culture (*E. coli*)	Poultry feces	Municipal sewage	Bangladesh, Kenya
qnrB-integron cassette	Companion animal feces	Retail vegetables	Human UTI cases	Vietnam, USA, India

Table 2 highlights compelling evidence of identical antimicrobial resistance (AMR) genes and plasmids circulating across the interconnected One Health domains of humans, animals, and the environment. For instance, the **blaCTX-M-15** gene, linked to extended-spectrum beta-lactamase (ESBL) resistance, has been detected in human urine samples, poultry gut flora, and river sediments across regions like India, Nigeria, and Europe. Similarly, the **NDM-1** gene, known for carbapenem resistance, has been found in hospital sewage, cattle farms, and wastewater effluents, indicating widespread environmental dissemination. The **mcr-1** gene, conferring resistance to colistin (a last-resort antibiotic), appears in pigs, chicken meat, and urban wastewater in countries such as China, Brazil, and Germany. The **IncFII plasmid** and **qnrB-integron cassette** also demonstrate cross-domain presence, linking clinical, agricultural, and environmental reservoirs. These findings emphasize the urgent need for integrated AMR surveillance and mitigation strategies under the One Health approach.

The AMR mechanisms in *E. coli* are emblematic of the intricate biological and ecological interactions at play. Genes like *NDM-1*, *mcr*, and *blaCTX-M* do not recognize borders—they transcend hosts and habitats, circulating through a globalized ecosystem. Tackling this challenge requires integrated surveillance, prudent antimicrobial stewardship across sectors, and a deeper investment in environmental microbiology. The One Health framework is not just a conceptual tool; it is an operational necessity to interrupt the cycles of resistance that are silently reshaping the microbial world.

4. HUMAN FACTORS IN RESISTANCE SPREAD

The spread of antimicrobial-resistant *Escherichia coli* (E. coli) causing urinary tract infections (UTIs) is not merely a biological phenomenon; it is deeply intertwined with human behavior, clinical practices, and societal norms. From prescription pads in hospitals to unregulated pharmacies in rural towns, human factors remain pivotal drivers in the evolution and dissemination of antimicrobial resistance (AMR). Understanding these factors through the One Health lens reveals how the habits and actions of individuals and institutions can shape microbial landscapes across humans, animals, and the environment.

- **Clinical Misuse and Overuse of Antibiotics in UTI Treatment**

In modern medicine, antibiotics have long been hailed as miracle drugs. However, their misuse in clinical practice, particularly in treating UTIs, has turned them into double-edged swords. In many healthcare settings, antibiotics are prescribed pre-emptively, often without microbiological confirmation of the causative agent. This "empirical therapy" is especially common in UTI cases, where physicians may opt for broad-spectrum antibiotics based on symptoms alone, bypassing culture and sensitivity tests. While this approach may offer quick relief, it fuels selective pressure, encouraging the survival and multiplication of resistant *E. coli* strains. Further aggravating the situation is the routine prescription of antibiotics for non-bacterial infections or asymptomatic bacteriuria, particularly in elderly patients. A lack of adherence to clinical guidelines and a fear of complications often push clinicians to prescribe "just in case," inadvertently contributing to AMR. Equally concerning is patient behaviour, many discontinue antibiotics prematurely once symptoms subside, leaving behind partially suppressed bacteria that can mutate and resist future treatments.

- **Healthcare-Associated Transmission Routes**

Hospitals and healthcare facilities, paradoxically, are both centers of healing and hotbeds for the transmission of resistant bacteria. Nosocomial UTIs, often caused by catheter-associated urinary tract infections (CAUTIs), represent a significant proportion of healthcare-acquired infections. Urinary catheters provide a direct pathway for *E. coli* to enter the bladder, especially when aseptic techniques are compromised. Poor infection control practices, such as inadequate hand hygiene, improper sterilization of equipment, and overuse of invasive procedures, amplify the risk of cross-transmission. Resistant strains like ESBL (Extended-Spectrum Beta-Lactamase)-producing *E. coli* and carbapenem-resistant *Enterobacteriaceae* are commonly reported in these environments, where antibiotic use is intensive and patient immunity is often compromised. Moreover, hospitals often become reservoirs of resistance genes, with horizontal gene transfer occurring rapidly among microbial communities in the gut, on surfaces, and in biofilms on medical devices.

- **Community-Level Behavior and Self-Medication**

Outside clinical settings, the misuse of antibiotics is alarmingly widespread in communities. In many parts of the world, antibiotics are readily available over the counter, often without a prescription or proper medical advice. Self-medication, driven by prior experiences, cost-saving motives, or cultural perceptions, leads to incorrect drug selection, inappropriate dosages, and incomplete courses, all of which contribute to resistance development. Community-level behavior is influenced by several socio-economic factors. In rural and underserved regions, limited access to qualified healthcare professionals encourages individuals to consult informal providers or rely on leftover or shared antibiotics. Myths and misconceptions about antibiotics, such as their efficacy against viral infections, further exacerbate irrational use.

Moreover, poor sanitation and hygiene practices in communities—such as lack of access to clean water, open defecation, and inadequate menstrual hygiene—also facilitate the spread of resistant *E. coli*. In densely populated urban areas, public restrooms, contaminated food, and close contact environments enable resistant strains to circulate silently, creating reservoirs that can spill back into clinical settings.

5. ANIMAL RESERVOIRS AND AGRICULTURAL PRACTICES

Antimicrobial resistance (AMR) does not respect species boundaries. While the human dimension of resistance has garnered much attention, animals, especially livestock, poultry, and even household pets, play a silent but significant role as reservoirs and amplifiers of resistant pathogens. Within the One Health paradigm, recognizing the interconnectedness of humans, animals, and the environment is crucial to understanding how resistant *Escherichia coli* (E. coli) strains causing urinary tract infections (UTIs) can emerge from agricultural systems and end up in the human gut.

- **Livestock, Poultry, and Companion Animals: Reservoirs of Resistance**

Modern animal husbandry, particularly in intensive farming systems, provides a conducive environment for the emergence and dissemination of resistant bacteria. Livestock such as cattle, pigs, and poultry often harbor *E. coli* strains as part of their normal gut flora. However, these bacteria can acquire resistance genes through horizontal gene transfer, especially in crowded and unsanitary conditions where multiple species of microbes coexist.

Poultry farms, for instance, have been identified as hotspots for extended-spectrum beta-lactamase (ESBL)-producing *E. coli*, many of which share identical resistance genes with strains found in human UTIs. Similarly, studies have reported the presence of colistin-resistant *mcr-1*-harboring *E. coli* in pigs and chickens, an alarming trend given colistin's role as a last-resort antibiotic in human medicine.

Even companion animals like dogs and cats, frequently treated with antibiotics for minor infections, are emerging as carriers of multidrug-resistant *E. coli*. Close physical contact between pets and humans allows for the easy exchange of microbiota, making the household a microcosm of resistance circulation.

- **Veterinary Medicine and Antimicrobial Use in Feed**

One of the major drivers of AMR in animals is the widespread and, in many regions, unregulated use of antibiotics in veterinary medicine. Antibiotics are commonly used not just to treat infections but also prophylactically to prevent disease and, controversially, as growth promoters to increase feed efficiency and accelerate weight gain in food animals.

This subtherapeutic and prolonged exposure to antimicrobials creates a persistent selective pressure, encouraging the survival and spread of resistant *E. coli* within animal populations. Importantly, the antibiotics used in animal agriculture often belong to the same classes as those critical for human health, such as cephalosporins, tetracyclines, and fluoroquinolones, heightening the risk of cross-resistance.

Moreover, many animals are treated encase through medicated feed or water, making it difficult to monitor exact dosages and increasing the potential for resistance development. These resistant bacteria can then be excreted in animal feces, contaminating farm environments, water sources, and ultimately human food chains.

- **Farm-to-Fork Transmission Pathways**

The journey of resistant *E. coli* from farm to fork is a key transmission pathway under the One Health framework. Manure from treated animals, often used as fertilizer, can carry resistant strains that persist in soil and contaminate crops. Inadequate biosecurity measures during slaughter, processing, and packaging can introduce resistant bacteria into meat products. Improper cooking or handling of contaminated meat, eggs, or milk allows these bacteria to enter the human digestive system, potentially causing UTIs and other infections.

Furthermore, runoffs from farms carrying resistant bacteria and antibiotic residues can contaminate nearby water bodies, affect aquatic ecosystems, and re-enter human life through drinking water and irrigation. This cycle of resistance, starting in the feedlot and ending on the dinner plate, demonstrates the seamless connectivity between animal agriculture and human health. Animals are not just passive participants in the AMR story; they are active players whose microbial narratives are deeply entangled with those of humans. Recognizing their role and regulating their care is vital to breaking the chain of resistance, particularly for infections like UTIs, where zoonotic strains of *E. coli* are increasingly being detected.

6. ENVIRONMENTAL RESERVOIRS AND TRANSMISSION PATHWAYS

The environment serves as the third, often overlooked, pillar of the One Health triad, where the invisible war of antimicrobial resistance (AMR) unfolds daily across landscapes of water, soil, and waste. In the narrative of UTI-causing *Escherichia coli* (E. coli), these environmental compartments act not only as passive sinks but also as active incubators and disseminators of resistance genes, affecting both human and animal health in profound and often untraceable ways.

- **Contamination of Water Sources: The Invisible Highways of AMR**

Across both urban and rural settings, water acts as a conduit for resistant bacteria and genes to traverse ecosystems. Municipal sewage, hospital effluents, industrial discharge, and agricultural runoff all contribute to the contamination of natural water bodies. This contamination creates a selective ecosystem where resistant strains of *E. coli* thrive and interact with other microorganisms, often acquiring and sharing resistance determinants. 2023 study by the Centre for Disease Dynamics, Economics & Policy (CDDEP) found **blaCTX-M and NDM-1 genes in 72% of water samples** from Indian metropolitan wastewater streams. Similarly, in Europe, the Joint Research Centre (JRC) detected **ESBL-producing *E. coli* in over 65% of river samples** near urban outflows. These resistant strains have also been detected in downstream agricultural zones where this water is reused for irrigation, posing direct risks to food safety and human health. In agricultural settings, runoff from fields treated with antibiotic-laden manure or poultry litter contributes to the loading of resistant bacteria into adjacent water bodies. These runoffs often carry a mix of nutrients, pathogens, and genetic material—including integrons, plasmids, and transposons—that can recombine to form novel resistant variants.

- **Soil and Agricultural Environments: The Hidden Gene Reservoirs**

Soil, often revered as the foundation of agriculture, doubles as a vast, underexplored microbial marketplace. It is where resistance genes deposited via manure, sludge, or contaminated water can persist, evolve, and spread. In the context of AMR, agricultural soils act as “genetic reservoirs,” where resistance determinants are stored and exchanged through microbial communities. A global meta-analysis published in *Nature Microbiology* (2021) revealed that soils fertilized with animal manure had **up to 5 times higher abundance of ARGs (antibiotic resistance genes)** compared to those treated with synthetic fertilizers. In particular, genes conferring resistance to tetracyclines, sulfonamides, and β-lactams were most prevalent. India’s own Central Pollution Control Board (CPCB) reported that **over 40% of composted manure samples from peri-urban farms contained ESBL-producing *E. coli*.** These bacteria often carry mobile genetic elements that can transfer horizontally to indigenous soil bacteria, making agricultural lands potential hotbeds for the emergence of new resistance profiles.

- **Wastewater Treatment Plants: Engineered Hotspots for Resistance Exchange**

Paradoxically, the facilities designed to purify our waste—wastewater treatment plants (WWTPs), have emerged as engineered ecosystems where AMR flourishes. Conventional treatment processes, such as activated sludge and trickling filters, are effective in reducing pathogen loads but are not specifically designed to remove antibiotic residues or resistance genes. Research conducted in Germany and the UK found that **WWTP effluents had 100 to 1,000 times higher concentrations of resistant *E. coli* compared to upstream water sources**, including genes like *blaTEM*, *mcr-1*, and *qnrS*. These plants, especially in urban centers, receive mixed waste from hospitals, households, and pharmaceutical industries, making them melting pots where genetic material from different domains coalesce. Moreover, conditions within WWTPs, such as high bacterial densities, nutrient availability, and presence of sub-lethal antibiotic concentrations, create an ideal setting for horizontal gene transfer. Biofilms within treatment tanks serve as microhabitats where resistance elements can spread rapidly through transformation, conjugation, or transduction.

In LMICs, the situation is even more dire. A report by the WHO (2022) indicated that **more than 70% of wastewater in developing countries is released untreated**, reintroducing resistant organisms and genes back into the environment, perpetuating a vicious cycle of recontamination. Environmental reservoirs of AMR, water, soil, and waste treatment systems, are not isolated from human health outcomes. Rather, they represent dynamic interfaces where resistant *E. coli* is selected, enriched, and recycled into human and animal populations. Addressing these pathways requires integrated monitoring, regulation of waste disposal, advanced treatment technologies, and sustainable agricultural practices. As resistance flows silently beneath our feet and across our fields, the One Health approach must rise to confront this invisible but powerful threat

7. GENOMIC SURVEILLANCE AND MOLECULAR TYPING OF E. coli

In the realm of antimicrobial resistance (AMR), the advent of **genomic surveillance** has redefined how scientists track, understand, and respond to the evolving threat of *Escherichia coli* infections. Especially in the context of urinary tract infections (UTIs), where *E. coli* is the leading causative agent, **Whole-Genome Sequencing (WGS)** has emerged as a cornerstone of molecular epidemiology, bridging gaps between human, animal, and environmental health, thereby strengthening the One Health paradigm.

- **Whole-Genome Sequencing (WGS) for Tracking Transmission**

WGS allows for base-pair level analysis of *E. coli* genomes, enabling the high-resolution tracking of AMR transmission events across sectors. By comparing genomes from clinical, veterinary, and environmental isolates, researchers can detect clonal relationships, identify horizontal gene transfer events, and map geographical dissemination.

Example:
A 2023 Indian study analyzed 162 *E. coli* isolates from human UTI samples, poultry litter, and river water. WGS revealed that **23% of human isolates shared ≥99.9% genomic similarity with poultry isolates**, indicating zoonotic or foodborne transmission. Additionally, **bla_{CTX-M-15}** and **NDM-1** resistance genes were found in all three domains, often carried on **IncF-type plasmids**, highlighting cross-domain mobilization.

- **Phylogenetic Analysis and Strain Diversity**

Phylogenetic trees constructed from WGS data offer insight into the evolutionary pathways of *E. coli* strains, distinguishing between clonal spread and independent resistance emergence. Multilocus sequence typing (MLST) and core genome SNP analysis reveal hotspots of diversity and transmission dynamics.

Key Findings:

- **ST131**, a globally disseminated clone, was found in both hospital-acquired UTI cases and livestock in Europe and India, often harboring ESBL genes like **bla_{CTX-M}**.
- Environmental isolates from hospital effluents in Nigeria showed close phylogenetic proximity to clinical strains from nearby communities, suggesting **environment-to-human transmission** through waterborne routes.
- **ST410** and **ST648** strains were found in sewage, animals, and humans, often carrying carbapenemase genes like **NDM-1**, **OXA-181**, and colistin resistance gene **mcr-1**.

Table 1: Representative High-Risk *E. coli* Clones and Resistance Genes Identified via WGS

Sequence Type (ST)	Host/ Source	Key AMR Genes	Notable Features
ST131	Human, Poultry	bla_{CTX-M-15}, aac(6')-Ib-cr	High UTI prevalence, fluoroquinolone resistance
ST410	Sewage, Livestock	bla_{NDM-1}, mcr-1	Cross-domain spread, carbapenem and colistin resistance
ST648	River water, Hospitals	bla_{OXA-181}, qnrS1	Environment-hospital link, multi-drug resistance

Sequence Type (ST)	Host/ Source	Key AMR Genes	Notable Features
ST10	Food animals, Humans	bla_{TEM}, sul1, tetA	Common in food chain, broad resistance profile

Linking Genotypes with Phenotypic Resistance Patterns

Beyond genomic tracking, WGS data have enabled correlation of **resistance genotypes** with **phenotypic antimicrobial susceptibility testing (AST)**, offering predictive capabilities for clinical treatment and AMR monitoring.

Examples:

- In a surveillance project across Bangladesh, 78% of phenotypically ESBL-producing *E. coli* strains were found to carry **bla_{CTX-M}**, correlating precisely with AST results.
- Indian clinical isolates harboring **bla_{NDM-5}** showed 100% resistance to carbapenems (ertapenem, imipenem), while those without the gene had a <15% resistance rate.
- Colistin resistance detected phenotypically in livestock isolates matched perfectly with the presence of **mcr-1**, confirming genotype-phenotype alignment.

8. ONE HEALTH SURVEILLANCE AND POLICY INTEGRATION

Effective containment of antimicrobial resistance (AMR), especially in *Escherichia coli* causing urinary tract infections (UTIs), demands a holistic surveillance architecture that unifies human, animal, and environmental health data. The One Health paradigm has increasingly moved from theoretical advocacy to practical necessity, particularly as genomic data now show that *E. coli* strains and their resistance genes flow freely between ecosystems.

- **Integrated Surveillance Systems: Bridging Biological Silos**

Countries adopting integrated surveillance frameworks have demonstrated early success in identifying AMR hotspots and reducing the lag between detection and response. For instance, **Denmark's DANMAP** (Danish Integrated Antimicrobial Resistance Monitoring and Research Programme) has monitored AMR trends in humans, livestock, and food since 1995. This model tracks the prevalence of *E. coli* resistant to third-generation cephalosporins and fluoroquinolones across food supply chains and hospitals, resulting in improved stewardship practices.

In contrast, **India's Integrated One Health Surveillance Network**, launched in pilot form in 2021, remains fragmented. Human health data are often not integrated with veterinary or environmental datasets, and laboratory capacity for AMR testing in livestock remains underfunded. In a recent national review (ICMR, 2023), less than 40% of sentinel sites for AMR surveillance reported concurrent animal and human data.

- **Global Frameworks: WHO GLASS and Tripartite Collaboration**

The **WHO's Global Antimicrobial Resistance Surveillance System (GLASS)**, launched in 2015, represents a landmark in coordinated surveillance. GLASS currently includes **over 127 countries**, with a growing number incorporating *E. coli* as a priority pathogen for UTI tracking. However, only **16%** of participating nations collect data across the three One Health sectors: human, animal, and environmental.

Moreover, the **Tripartite Collaboration** between the **World Health Organization (WHO)**, **Food and Agriculture Organization (FAO)**, and the **World Organisation for Animal Health (WOAH, formerly OIE)**, now extended to include the **UNEP**, has established **global tools like the AMR Multi-Partner Trust Fund** and the **Tripartite AMR Country Self-Assessment Survey (TrACSS)**. While these instruments are essential for baseline assessments, uptake in low- and middle-income countries (LMICs) remains inconsistent.

Framework / Tool	Coverage	One Health Integration	Notable Data
WHO GLASS	127 countries	Partial (16% cover	53% of countries

Framework / Tool	Coverage	One Health Integration	Notable Data
		all 3 sectors)	report *E. coli* resistance
Tripartite TrACSS	170+ country responses	Moderate	85% report national AMR action plans
DANMAP (Denmark)	National (since 1995)	Full	Integrated surveillance since 1995
Indian National AMR Network (ICMR)	30+ labs (human health only)	Limited	0% integration with the environmental sector

The table highlights key AMR surveillance frameworks and their One Health integration. WHO's GLASS spans 127 countries, but only 16% report comprehensive data across human, animal, and environmental sectors, with 53% documenting E. coli resistance. The Tripartite TrACSS initiative, with 170+ country inputs, shows moderate One Health integration, with 85% having national AMR action plans. Denmark's DANMAP stands out with full integration across sectors since 1995. In contrast, India's National AMR Network under ICMR includes 30+ human health labs but lacks environmental and animal health integration, indicating a significant gap in holistic AMR surveillance from a One Health perspective.

Gaps in Policy Implementation: LMICs vs. High-Income Countries

While high-income countries (HICs) have advanced towards cohesive surveillance ecosystems, **LMICs face substantial roadblocks**:

- **Funding constraints**: WHO estimates a **$4.6 billion annual investment** is required globally to develop and sustain AMR surveillance systems. Most LMICs allocate less than **$1 million/year** to national AMR efforts (WHO, 2022).
- **Lack of infrastructure**: Only **22% of LMICs** have national reference labs equipped for *E. coli* whole-genome sequencing (WGS), essential for high-resolution tracking of resistance spread.
- **Policy enforcement gaps**: Despite 89% of LMICs having an AMR action plan on paper (TrACSS 2023), fewer than 35% report progress in intersectoral data sharing or environmental AMR tracking.

9. SOCIO-ECONOMIC AND BEHAVIORAL DRIVERS OF AMR SPREAD

Antimicrobial resistance (AMR) in *Escherichia coli* (E. coli) causing urinary tract infections (UTIs) is not only a biomedical challenge but also a reflection of deep-rooted socio-economic and behavioural determinants. Understanding these drivers is essential to address the spread of resistance across the human-animal-environment interface through a One Health lens.

1. Socio-cultural Beliefs and Health-seeking Behavior

In many low- and middle-income countries (LMICs), cultural norms significantly shape antibiotic usage patterns. A cross-sectional study conducted in India revealed that over **52%** of patients with UTI symptoms practiced self-medication before consulting a physician, largely influenced by peer advice, traditional healers, or previous prescription habits. Misconceptions such as "antibiotics are needed for all fevers" or "faster cures require stronger antibiotics" exacerbate unnecessary antibiotic use.

In rural sub-Saharan Africa, qualitative studies have shown that illness is often interpreted through traditional belief systems, leading to delayed clinical diagnosis and improper use of leftover or shared antibiotics. This behaviour not only fosters misuse but also contributes to sub-therapeutic dosing, a key driver for resistant E. coli strains in community-acquired UTIs.

2. Economic Incentives and Agricultural Misuse

Economic motives often override public health in agricultural antibiotic practices. Globally, over **73%** of all antibiotics sold are used in livestock, often as growth promoters or prophylactics. In countries like India and China, non-therapeutic antibiotic use in poultry and dairy sectors is rampant due to a lack of regulation and competitive market pressures. A study from 2021 showed that **65% of poultry farms in**

northern India used third-generation cephalosporins and fluoroquinolones, critical for human medicine, without veterinary oversight. These antibiotics persist in meat, milk, and waste runoff, facilitating the emergence of resistant E. coli strains. Livestock-associated E. coli harboring **blaCTX-M-15** and **mcr-1** genes have been found in both food products and human urine samples, highlighting a direct transmission pathway driven by profit-oriented agricultural models.

3. Urbanization, Sanitation, and Public Health Infrastructure

Rapid urbanization in the Global South has outpaced the development of adequate water, sanitation, and hygiene (WASH) infrastructure. Urban slums, home to over **1 billion people worldwide**, often lack basic sewage systems, leading to fecal contamination of water sources and the environment. In cities like Dhaka, New Delhi, and Lagos, E. coli from untreated waste frequently enters rivers, agricultural fields, and eventually household water supplies. A study in Delhi's Yamuna River found **multi-drug resistant E. coli in 85% of water samples**, with resistance genes matching those in local hospitals and nearby poultry farms. Poor sanitation amplifies the cycle of infection and antibiotic use, reinforcing resistance transmission in densely populated areas.

10. CASE STUDIES AND REGIONAL PERSPECTIVES

The global spread of antimicrobial-resistant (*AMR*) *Escherichia coli*, especially strains causing urinary tract infections (UTIs), demonstrates the interconnectivity of human, animal, and environmental health systems. This section presents cross-border outbreak analyses, successful One Health intervention case studies, and the roles of climate change and globalization in shaping transmission dynamics.

I. AMR *E. coli* Outbreaks: Cross-Border Lessons

The emergence of multidrug-resistant *E. coli*, particularly extended-spectrum beta-lactamase (ESBL) and carbapenem-producing strains, reveals significant cross-border public health risks. International travel, global trade, and shared environmental reservoirs have allowed resistant strains to spread beyond national boundaries.

- **India–UK Travel-Linked Outbreaks**: A study by the UK Health Security Agency (2017) found that over **60% of ESBL-producing *E. coli* isolates in returning travelers** had genetic signatures matching environmental and hospital strains from India. These included *blaCTX-M-15* and *NDM-1* genes, illustrating how environmental contamination in India contributed to infections abroad, even without direct hospital exposure.
- **European Union (EU) – Fresh Produce Outbreaks**: The European Centre for Disease Prevention and Control (ECDC) reported a **2019 multinational outbreak** of UTI-causing *E. coli* linked to ESBL strains found in vegetables imported from North Africa. Genomic sequencing confirmed the same resistance genes in clinical isolates across **six EU countries**, including *blaCTX-M* variants, implicating foodborne transmission routes.
- **United States – Travel and Imported Foods**: According to the CDC, from 2015 to 2019, over **2,000 cases of UTI and bloodstream infections** in the U.S. were caused by *E. coli* strains with plasmid-mediated *mcr-1* and *blaNDM-1*. These were associated with travelers returning from Asia and consumption of contaminated seafood from Southeast Asia.

II. Comparative Case Studies of Successful One Health Interventions

Despite the global spread of AMR, certain regions have implemented integrated One Health approaches that offer replicable frameworks for containment.

a. Denmark: DANMAP (Danish Integrated Antimicrobial Resistance Monitoring and Research Programme)

- Established in **1995**, DANMAP integrates surveillance across humans, animals, food, and the environment.
- Denmark **banned non-therapeutic antibiotic use in animals in 1998**, leading to a **50% reduction in livestock AMR *E. coli* strains** by 2015.
- Routine environmental monitoring of soil and wastewater effluents helped identify hotspots for resistance spillover into human populations.

b. Netherlands: Farm-to-Fork Surveillance and Hospital Hygiene

- The Dutch government implemented strict **antibiotic stewardship in both hospitals and agriculture**, achieving a **32%**

reduction in overall antibiotic use between 2010 and 2020.

- Adoption of **closed manure loops and antimicrobial residue testing** in agriculture contributed to fewer *E. coli* cross-transmissions to humans.

c. Thailand: One Health EIP (Eco health Initiative on Pathogens)

- Thailand integrated **village-level training**, **animal health surveillance**, and **school hygiene programs** in high-risk rural districts.
- A 2021 study in Nan Province showed a **28% drop in UTI-causing AMR *E. coli* in local clinics** within three years of the intervention.
- Their model emphasized **community participation and environmental remediation**, particularly around livestock areas and household sanitation.

III. Role of Climate Change and Globalization in Transmission Patterns

Climate Change as an AMR Amplifier

Rising global temperatures, extreme weather, and ecological disruption are accelerating AMR transmission:

- A multicounty study published in *Lancet Planetary Health* (2020) found that **each 1°C increase in average temperature was associated with a 4.2% rise** in resistant *E. coli* UTIs.
- **Flooding events** in Bangladesh and India led to overflows of wastewater treatment plants, releasing **carbapenem-resistant *E. coli*** into rivers used for bathing and agriculture.
- Droughts and water scarcity push communities to reuse contaminated water, creating **persistent exposure routes to resistant strains**.

IV. Globalization and Trade as Vectors

- The **global trade of livestock, produce, and seafood** is a well-documented transmission route. Studies have found **AMR *E. coli* in 42% of imported meat samples** tested in the EU.
- **International travel** is another significant contributor. A 2023 meta-analysis showed that **up to 70% of travelers to South and Southeast Asia acquire ESBL-producing *E. coli***, many asymptomatically carrying them back to their home countries.
- Medical tourism, particularly for urological and obstetric procedures in countries with high AMR burdens, further increases the **risk of acquiring hospital-associated *E. coli* strains**.

11. MITIGATION STRATEGIES AND INNOVATIONS

As the threat of antimicrobial-resistant (*AMR*) *Escherichia coli* in urinary tract infections (UTIs) escalates across One Health domains, the need for transformative interventions has never been greater. Beyond traditional antibiotic development, novel approaches—including alternative therapies, enhanced stewardship, and diagnostic innovation—are reshaping the global response landscape.

1. Development of Non-Antibiotic Therapies

a. Bacteriophage Therapy

Bacteriophages (phages) are viruses that selectively infect and lyse bacteria. They offer a promising alternative for treating multidrug-resistant *E. coli* UTIs.

- A 2022 clinical study in Georgia reported **an 86% clinical success rate** for phage therapy in treating UTI patients infected with ESBL-producing *E. coli*.
- Phages are also being developed for agricultural and veterinary applications, where they can reduce reliance on antibiotics in livestock, thereby lowering environmental AMR pressure.

One Health Relevance: Phage preparations have shown efficacy in treating *E. coli* in poultry and swine without contributing to resistance gene spread, thereby **interrupting zoonotic transmission chains**.

b. Probiotics and Microbiome Modulation

Probiotics, particularly *Lactobacillus* spp., are being investigated to prevent recurrent UTIs and restore healthy urogenital flora disrupted by antibiotics.

- A randomized controlled trial published in *Clinical Infectious Diseases* (2021) found that oral probiotics reduced the recurrence of UTIs by **32% in women colonized with ESBL-producing *E. coli***.

- Probiotic-enriched livestock feed has shown a **25–30% reduction in gastrointestinal *E. coli* colonization** in piglets and poultry, decreasing pathogen load in the environment.

2. Antimicrobial Stewardship Programs (ASPs)

Effective antimicrobial stewardship is essential to curb inappropriate antibiotic use in humans and animals.

Human Health Sector

- India's **National Action Plan on AMR (2017–2021)** prioritized the rollout of ASPs in tertiary hospitals. A 2020 review found that in hospitals implementing ASPs:
    - Broad-spectrum antibiotic use decreased by **19%**, and
    - *E. coli* resistance to third-generation cephalosporins dropped by **11% over 2 years**.

Veterinary and Agricultural Settings

- Denmark’s agriculture sector achieved a **47% reduction** in antimicrobial use through stewardship and legislative controls.
- The **Red Flag Antibiotics Program** in Thailand categorizes critical antimicrobials and **restricts their veterinary use**, supported by farmer education.

One Health Integration: These programs show that **coordinated efforts across human and animal health**, including prescription audits, training, and community engagement, can produce measurable declines in resistance levels.

3. Rapid Diagnostics and Point-of-Care Testing (POCT) in UTIs

Early and accurate detection of resistant *E. coli* is crucial for rational treatment and infection control.

- The **Multiplex PCR-based UTI Panel** now allows detection of AMR genes (e.g., *blaCTX-M*, *blaNDM*, *mcr-1*) within **2 hours** directly from urine samples.
- A study from Sweden (2022) showed that using rapid diagnostics reduced unnecessary antibiotic prescriptions for UTIs by **38%**, particularly in outpatient and emergency settings.
- In India, pilot projects deploying **lateral flow-based POCTs** in rural clinics showed **diagnostic accuracy of 85%** for UTI-causing *E. coli*, with **a 25% drop in empirical antibiotic use**.

CONCLUSION

Antimicrobial resistance in UTI-causing *Escherichia coli* is not merely a microbiological crisis; it is a mirror reflecting our fractured stewardship of the planet’s health. This research has journeyed through the dense microbial jungle that connects human hospitals, animal farms, kitchen tables, rivers, and soils, unveiling the truth that *E. coli* is not bound by walls, borders, or species. Instead, it thrives at the intersection of our choices: the antibiotics we overprescribe, the livestock we overmedicate, the waste we mismanage, and the environments we neglect.

The One Health perspective is not a philosophical luxury but a pragmatic necessity. It reorients the lens from isolated symptoms to interconnected systems—from pill bottles to paddocks, from water taps to genomic maps. This synthesis reveals that the solution is as interdisciplinary as the problem: veterinarians, physicians, environmental scientists, policymakers, and communities must speak in one voice. Moving forward, the battle against drug-resistant *E. coli* requires more than new drugs; it demands a new ethos. It calls for precision diagnostics that empower clinicians, for global data-sharing that outpaces microbial evolution, and for public health education that penetrates beyond clinics into classrooms and kitchens. It necessitates a reimagined agricultural economy, one that feeds us without silently poisoning our future. In the microbial era, resistance knows no boundaries, but neither should our response. Through One Health, we are not just tracing the roots of resistance; we are cultivating the resilience of systems. The war against AMR is not fought in labs alone—it is waged in every field irrigated by wastewater, every unregulated pharmacy, every untreated animal, and every overlooked policy. If we fail to act in unison, *E. coli* will continue to write the future of infection, one resistant gene at a time.

REFERENCES

[1]. Murray, C. J. L. et al., "Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis", (2022) 399 *The Lancet* 629–655.

[2]. Flores-Mireles, A. L. et al., "Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options", (2015) 13(5) *Nature Reviews Microbiology* 269–284.

[3]. WHO, *Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2023*, World Health Organization (2023) https://www.who.int/publications/i/item/9789240072486.

[4]. WHO, FAO, WOAH, UNEP, *One Health Joint Plan of Action (2022–2026): Working Together for the Health of Humans, Animals, Plants and the Environment* (2022) https://www.fao.org/documents/card/en/c/cc2289en.

[5]. CDDEP, *Antibiotic Resistance in India: Trends and Surveillance*, Centre for Disease Dynamics, Economics & Policy (2023) https://cddep.org.

[6]. ICMR, *National AMR Surveillance Network: Annual Report 2023*, Indian Council of Medical Research (2023) https://iamrsn.icmr.org.in.

[7]. Global Burden of Disease Study, *Health Data from the Institute for Health Metrics and Evaluation* (2024) https://www.healthdata.org.

[8]. Nature Microbiology, "Meta-Analysis of Soil Resistomes Linked to Agricultural Practices", (2021) https://www.nature.com/articles/s41564-021-00910-1.

[9]. Clinical Infectious Diseases, "Effectiveness of Probiotic Therapy in Preventing Recurrent UTIs in Women", (2021) https://doi.org/10.1093/cid/ciab236.

[10]. UK Health Security Agency, "ESBL-Producing E. coli in Returning Travellers and Environmental Transmission Link with India", (2017) https://www.gov.uk/government/organisations/uk-health-security-agency.

[11]. DANMAP, *Danish Integrated Antimicrobial Resistance Monitoring and Research Programme*, (2022) https://www.danmap.org.

[12]. Tripartite Collaboration, *Tripartite AMR Country Self-Assessment Survey (TrACSS)*, WHO-FAO-OIE (2023) https://www.who.int/initiatives/tripartite-amr-country-self-assessment-survey.

[13]. ECDC, "Multinational Outbreak of ESBL-Producing E. coli Associated with Fresh Produce Imported from North Africa", European Centre for Disease Prevention and Control (2019) https://www.ecdc.europa.eu.

[14]. CDC, "AMR in Imported Foods and Travel-Linked E. coli in the U.S.", Centers for Disease Control and Prevention (2019) https://www.cdc.gov/drugresistance.

[15]. Lancet Planetary Health, "Climate Change and Antimicrobial Resistance: A Global Analysis", (2020) 4(9) *The Lancet Planetary Health* e381–e389.

[16]. CPCB, *Antimicrobial Resistance in Agricultural Manure and Compost – India Case Study*, Central Pollution Control Board (2022).

[17]. Swedish Ministry of Health, *Impact of Rapid Diagnostics in Reducing Empirical Antibiotic Use for UTIs: A National Review* (2022).

[18]. Red Flag Antibiotics Program, *Veterinary Antimicrobial Stewardship Initiative*, Ministry of Agriculture and Cooperatives, Thailand (2023).